Citius Pharmaceuticals

CTXR

Market cap $15M

CTXR Hedge Fund Activity: Q1 2026 in Review

38 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q1 2026, worth a combined $897K — down 33% from $1.34M a quarter earlier.

Fund positioning in CTXR was balanced in Q1 2026: 9 funds opened new positions, 9 closed out, 7 added to existing stakes and 6 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $95.8K. The largest seller was Heights Capital Management, exiting entirely with an estimated $622K sold.

• 38 institutional investors held Citius Pharmaceuticals (CTXR) as of Q1 2026, down from 39 in Q4 2025.
• Funds reported $897K of Citius Pharmaceuticals stock for Q1 2026, down 33% quarter-over-quarter.
• 9 funds opened new Citius Pharmaceuticals positions in Q1 2026 and 9 closed out, a net change of 0 holders.
• The largest Citius Pharmaceuticals buyer in Q1 2026 was Geode Capital Management, an estimated $95.8K added.
• The largest Citius Pharmaceuticals seller in Q1 2026 was Heights Capital Management, an estimated $622K sold.

Based on aggregated 13F filings for Q1 2026.